Established in 2015, YuceBio is a leading all-in-one solution platform for tumor immunodiagnosis and treatment focusing on the assay capabilities of tumor neoantigens to carry out product development, transformation and promotion. YuceBio boasts a world-class tumor neoantigen assay and identification platform, a multi-dimensional tumor immunodiagnosis assay and study platform, a professional tumor immunodiagnosis bio-information interpretation database, and a database of real-world cases on tumor immunodiagnosis and treatment. The company relies on international high-standard studies and production quality systems as well as experienced management and operation teams to provide clinically accessible medication guidance and dynamic monitoring/testing products for cancer patients, to provide precision medicine solutions for medical institutions and service providers, and to provide pharmaceutical companies with high-quality services for companion diagnostic and treatment target development.
Since its inception, YuceBio has completed 4 rounds of financing totaling several hundred millions in RMB, built a third-party medical laboratory, and deployed an IVD R&D and production base in Jiangsu. It provides tumor clinical testing and clinical study, all-in-one solutions for pharmaceutical R&D services and clinical trials, and reagents for companion diagnostic-in vitro diagnosis (CDx-IVD), with 28 invention patents at home and abroad and 24 software copyrights. Its business covers more than 40 cities and 200 hospitals. In 2017, YuceBio and Academician Zhan Qimin jointly launched the first real-world study on tumor immunotherapy: "Ladder for Cancer Moonshot".
YuceBio has obtained the certifications of National High-Tech Enterprise and Shenzhen High-Tech Enterprise, and has become the first Chinese company in Asia to join the Tumor Neoantigen Selection Alliance (TESLA) and the first company in China to provide TMB (tumor mutation burden) testing, accumulating the most comprehensive tumor immunotherapy gene data in China. YuceBio is also the first institution in China to conduct dynamic monitoring studies on the efficacy of tumor immunotherapy.
YuceBio adheres to the mission of "making tumor immunotherapies more effective" and is committed to becoming China's No. 1 brand in precision medicine and tumor immunodiagnosis and treatment.
Shenzhen WiHealth Medical Laboratory (YuceLab) is a third-party independent medical laboratory approved by the Health and Family Planning Commission of Shenzhen Municipality. As a medical laboratory of YuceBio, YuceLab has always implemented a scientific, accurate, rigorous, and innovative quality policy to ensure the accuracy, reliability and safety of testing. For three consecutive years, it has delivered excellent results in the external quality assessment (EQA) and proficiency validation tests carried out by authoritative organizations at home and abroad, such as the National Center for Clinical Laboratory (NCCL) of the National Health Commission of the People's Republic of China, the College of American Pathologists (CAP), and the European Molecular Genetics Quality Network (EMQN).
The laboratory boasts the DNBSEQ-T7 and MGI2000 gene sequencers manufactured by MGI, Illumina sequencing platform, ddPCR validation platform, real-time fluorescence quantitative PCR platform, and immunohistochemistry platform. It has established the whole-process information system from sample reception, sample management, sample preparation, machine sequencing to information analysis, data interpretation, and report issuance. Moreover, it can update the genetic information database and clinical interpretation database in real time, realizing the full automation of data analysis and interpretation. The laboratory is committed to providing high-quality and well-prepared clinical laboratory services for clinic applications and delivering a full range of medical study services.
Copyright©2021
Shenzhen yucebio Technology Co., Ltd. all rights reserved
Yueicp no.16128839
